Joe Jimenez and Mark Fishman target $400M for third fund after leaving Novartis

For­mer No­var­tis CEO Joe Jimenez and re­search leader Mark Fish­man are fundrais­ing again for their life sci­ences firm Adi­tum Bio, which in-li­cens­es trans­la­tion­al-stage drugs and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.